van der Woude, L. L. et al. Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. J. Immunother. Cancer 10, e005248 (2022).
Google ScholarÂ
Zhang, Z., Liu, X., Chen, D. & Yu, J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct. Target. Ther. 7, 258 (2022).
Google ScholarÂ
Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925–931 (2012).
Google ScholarÂ
Harding, S. M. et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548, 466–470 (2017).
Google ScholarÂ
RodrÃguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C. & Demaria, S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 39, 644–655 (2018).
Google ScholarÂ
Gong, X. et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J. Thorac. Oncol. 12, 1085–1097 (2017).
Google ScholarÂ
Guo, S. et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct. Target. Ther. 8, 205 (2023).
Google ScholarÂ
Herrera, F. G. et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12, 108–133 (2022).
Google ScholarÂ
Storozynsky, Q. & Hitt, M. M. The impact of radiation-induced DNA damage on cGAS–STING-mediated immune responses to cancer. Int. J. Mol. Sci. 21, 8877 (2020).
Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. The cGAS–STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548–569 (2021).
Google ScholarÂ
Yang, Y. et al. ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Sci. Adv. 7, eabf6290 (2021).
Google ScholarÂ
Li, J. Y. et al. TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models. Nat. Commun. 14, 865 (2023).
Google ScholarÂ
Wang, L. et al. STING agonist-loaded nanoparticles promotes positive regulation of type I interferon-dependent radioimmunotherapy in rectal cancer. Adv. Sci. 11, e2307858 (2024).
Google ScholarÂ
Li, T. & Chen, Z. J. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J. Exp. Med. 215, 1287–1299 (2018).
Google ScholarÂ
Stark, G. R. & Darnell, J. E. Jr The JAK-STAT pathway at twenty. Immunity 36, 503–514 (2012).
Google ScholarÂ
Fan, J. B. et al. Type I interferon regulates a coordinated gene network to enhance cytotoxic T cell-mediated tumor killing. Cancer Discov. 10, 382–393 (2020).
Google ScholarÂ
Huang, K. C. et al. Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy. J. Iimmunother. Cancer 12, e008515 (2024).
Wang, Y. et al. cGAS–STING pathway in cancer biotherapy. Mol. Cancer 19, 136 (2020).
Google ScholarÂ
Khosravi, G. R. et al. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. 44, 521–553 (2024).
Google ScholarÂ
Jiang, W., Chan, C. K., Weissman, I. L., Kim, B. Y. S. & Hahn, S. M. Immune priming of the tumor microenvironment by radiation. Trends Cancer 2, 638–645 (2016).
Google ScholarÂ
Lynch, C., Pitroda, S. P. & Weichselbaum, R. R. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 25, e352–e362 (2024).
Google ScholarÂ
Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687–695 (2014).
Google ScholarÂ
Seyedin, S. N. et al. Combination therapy with radiation and PARP inhibition enhances responsiveness to anti-PD-1 therapy in colorectal tumor models. Int. J. Radiat. Oncol. Biol. Phys. 108, 81–92 (2020).
Google ScholarÂ
Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379–5388 (2009).
Google ScholarÂ
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N. & Formenti, S. C. Emerging evidence for adapting radiotherapy to immunotherapy. Nat. Rev. Clin. Oncol. 20, 543–557 (2023).
Google ScholarÂ
Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919–1929 (2017).
Google ScholarÂ
Spigel, D. R. et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J. Clin. Oncol. 40, 1301–1311 (2022).
Google ScholarÂ
Bradley, J. D. et al. Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study. J. Clin. Oncol. 43, 3610–3621 (2025).
Google ScholarÂ
Schoenfeld, J. D. et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 23, 279–291 (2022).
Google ScholarÂ
Burnette, B. C. et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 71, 2488–2496 (2011).
Google ScholarÂ
Wang, X. et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 77, 839–850 (2017).
Google ScholarÂ
Long, Y. et al. GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer. Signal Transduct. Target. Ther. 8, 48 (2023).
Google ScholarÂ
Boukhaled, G. M., Harding, S. & Brooks, D. G. Opposing roles of type I interferons in cancer immunity. Annu. Rev. Pathol. 16, 167–198 (2021).
Google ScholarÂ
Goedegebuure, R. S. A. et al. Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. J. Exp. Clin. Cancer Res. 40, 161 (2021).
Google ScholarÂ
Wang, X. et al. UbiBrowser 2.0: a comprehensive resource for proteome-wide known and predicted ubiquitin ligase/deubiquitinase-substrate interactions in eukaryotic species. Nucleic Acids Res. 50, D719–D728 (2022).
Google ScholarÂ
Wahlström, A., Sayin, S. I., Marschall, H. U. & Bäckhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50 (2016).
Google ScholarÂ
Mueller, M. et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J. Hepatol. 62, 1398–1404 (2015).
Google ScholarÂ
Lazaridis, K. N., Gores, G. J. & Lindor, K. D. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J. Hepatol. 35, 134–146 (2001).
Google ScholarÂ
Kim, M. J. et al. Ursodeoxycholate restores biliary excretion of methotrexate in rats with ethinyl estradiol induced-cholestasis by restoring canalicular Mrp2 expression. Int. J. Mol. Sci. 19, 1120 (2018).
Carey, E. J., Ali, A. H. & Lindor, K. D. Primary biliary cirrhosis. Lancet 386, 1565–1575 (2015).
Google ScholarÂ
Ocaña, A. & Pandiella, A. Proteolysis targeting chimeras (PROTACs) in cancer therapy. J. Exp. Clin. Cancer Res. 39, 189 (2020).
Google ScholarÂ
Schneider, M. et al. The PROTACtable genome. Nat. Rev. Drug Discov. 20, 789–797 (2021).
Google ScholarÂ
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Google ScholarÂ
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284–287 (2012).
Google ScholarÂ
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
Google ScholarÂ
Castro-Mondragon, J. A. et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 50, D165–D173 (2022).
Google ScholarÂ
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
Google ScholarÂ
Li, J. et al. The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins 79, 2794–2812 (2011).
Google ScholarÂ
Yan, Y., Zhang, D., Zhou, P., Li, B. & Huang, S. Y. HDOCK: a web server for protein-protein and protein-DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res. 45, W365–W373 (2017).
Google ScholarÂ
